Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

161. Natalizumab (Tysabri) for secondary progressive multiple sclerosis

Natalizumab (Tysabri) for secondary progressive multiple sclerosis Natalizumab (Tysabri) for secondary progressive multiple sclerosis Natalizumab (Tysabri) for secondary progressive multiple sclerosis NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Natalizumab (Tysabri) for secondary progressive multiple sclerosis. Birmingham: NIHR Horizon (...) Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Natalizumab (Tysabri) is intended for the treatment of secondary progressive multiple sclerosis (SPMS) in patients who have progressed from relapsing remitting MS. If licensed, natalizumab will offer an additional treatment option for patients with SPMS, a group who currently have few effective therapies available. No disease-modifying drugs are currently licensed specifically for SPMS. Natalizumab is a selective

2015 Health Technology Assessment (HTA) Database.

162. Masitinib for primary and relapse-free secondary progressive multiple sclerosis - first line

Masitinib for primary and relapse-free secondary progressive multiple sclerosis - first line Masitinib for primary and relapse-free secondary progressive multiple sclerosis – first line Masitinib for primary and relapse-free secondary progressive multiple sclerosis – first line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Masitinib (...) for primary and relapse-free secondary progressive multiple sclerosis – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Masitinib is intended to be used as first line therapy for the treatment of primary progressive or relapse-free secondary progressive multiple sclerosis. If licensed, masitinib will offer a novel, oral treatment option for this patient group for whom no licensed therapies are currently available. Masitinib

2015 Health Technology Assessment (HTA) Database.

163. Rehabilitation in multiple sclerosis

Rehabilitation in multiple sclerosis Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis | Neurology Advertisement Search for this keyword Main menu User menu Search Search for this keyword The most widely read and highly cited peer-reviewed neurology journal Share November 24, 2015 ; 85 (21) Special Article Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis Report of the Guideline Development, Dissemination, and Implementation (...) Getchius Gary Gronseth Melissa J. Armstrong Pushpa Narayanaswami Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis Jodie K. Haselkorn , Christina Hughes , Alex Rae-Grant , Lily Jung Henson , Christopher T. Bever , Albert C. Lo , Theodore R. Brown , George H. Kraft , Thomas Getchius , Gary Gronseth , Melissa J. Armstrong , Pushpa Narayanaswami Neurology Nov 2015, 85 (21) 1896-1903; DOI: 10.1212/WNL.0000000000002146 Citation Manager Formats Make Comment See Comments

2015 American Academy of Neurology

164. Cohort study: The human papillomavirus vaccination is not associated with risk of multiple sclerosis or other demyelinating diseases

Cohort study: The human papillomavirus vaccination is not associated with risk of multiple sclerosis or other demyelinating diseases The human papillomavirus vaccination is not associated with risk of multiple sclerosis or other demyelinating diseases | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The human papillomavirus vaccination is not associated with risk of multiple sclerosis or other demyelinating diseases Article Text

2015 Evidence-Based Medicine

165. Management of Multiple Sclerosis

Management of Multiple Sclerosis Management of Multiple Sclerosis Published by: Malaysia Health Technology Assessment Section (MaHTAS) Medical Development Division, Ministry of Health Malaysia Level 4, Block E1, Precinct 1 Federal Government Administrative Centre 62590, Putrajaya, Malaysia Copyright The copyright owner of this publication is MaHTAS. Content may be reproduced in any number of copies and in any format or medium provided that a copyright acknowledgement to MaHTAS is included (...) of the related specialty will be informed about it. A discussion will be done on the need for a revision including the scope of the revised CPG. A multidisciplinary team will be formed and the latest systematic review methodology used by MaHTAS will be employed. Management of Multiple Sclerosis TABLE OF CONTENTS No. Title Page Levels of Evidence & Formulation of Recommendation i Guidelines Development and Objectives ii Guidelines Development Group v Review Committee vi External Reviewers vii Algorithm 1

2015 Ministry of Health, Malaysia

166. Dimethyl fumarate (multiple sclerosis ? relapsing-remitting) ? Benefit assessment according to §35a Social Code Book V

Dimethyl fumarate (multiple sclerosis ? relapsing-remitting) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dimethylfumarat – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 July 2014). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A14 (...) ? Sarah Mostardt ? Katrin Nink ? Sibylle Sturtz ? Beate Wieseler ? Min Zhou Keywords: dimethyl fumarate, multiple sclerosis – relapsing-remitting, benefit assessment 2 Due to legal data protection regulations, employees have the right not to be named. Extract of dossier assessment A14-14 Version 1.0 Dimethyl fumarate – Benefit assessment acc. to §35a Social Code Book V 30 July 2014 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List

2014 Institute for Quality and Efficiency in Healthcare (IQWiG)

167. Daclizumab High Yield Process for relapsing forms of multiple sclerosis ? first or second line

Daclizumab High Yield Process for relapsing forms of multiple sclerosis ? first or second line Daclizumab High Yield Process for relapsing forms of multiple sclerosis – first or second line Daclizumab High Yield Process for relapsing forms of multiple sclerosis – first or second line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation NIHR HSC. Daclizumab High Yield Process for relapsing forms of multiple sclerosis – first or second line. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanizeds; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting Language Published English Country of organisation England English summary An English language summary is available. Address

2014 Health Technology Assessment (HTA) Database.

168. Ocrelizumab for relapsing-remitting multiple sclerosis

Ocrelizumab for relapsing-remitting multiple sclerosis Ocrelizumab for relapsing-remitting multiple sclerosis Ocrelizumab for relapsing-remitting multiple sclerosis NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Ocrelizumab for relapsing-remitting multiple sclerosis. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC (...) ). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Humans; Multiple Sclerosis, Relapsing-Remitting Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Centre, School of Health&Population Sciences, University of Birmingham, Public Health building, Edgbaston, Birmingham, B15 2TT. Tel: +44 121 414 7831

2014 Health Technology Assessment (HTA) Database.

169. Ocrelizumab for primary progressive multiple sclerosis

Ocrelizumab for primary progressive multiple sclerosis Ocrelizumab for primary progressive multiple sclerosis Ocrelizumab for primary progressive multiple sclerosis NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Ocrelizumab for primary progressive multiple sclerosis. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC (...) ). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Multiple Sclerosiss Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Centre, School of Health&Population Sciences, University of Birmingham, Public Health building, Edgbaston, Birmingham, B15 2TT. Tel: +44 121 414 7831 Email: nihrhsc

2014 Health Technology Assessment (HTA) Database.

170. Dimethyl fumarate for treating relapsing-emitting multiple sclerosis

Dimethyl fumarate for treating relapsing-emitting multiple sclerosis Dimeth Dimethyl fumar yl fumarate for treating ate for treating relapsing-remitting multiple sclerosis relapsing-remitting multiple sclerosis T echnology appraisal guidance Published: 27 August 2014 nice.org.uk/guidance/ta320 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 59Contents Contents 1 Guidance 4 2

2014 National Institute for Health and Clinical Excellence - Technology Appraisals

171. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex) - for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis

Delta-9-tetrahydrocannabinol/cannabidiol (Sativex) - for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis Final Appraisal Recommendation Advice No: 1814 – July 2014 Delta-9-tetrahydrocannabinol/cannabidiol (Sativex ® ) 2.7 mg/2.5 mg oromucosal spray Submission by GW Pharmaceuticals Plc In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 644), which (...) patients with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti- spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.

2014 All Wales Medicines Strategy Group

172. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study (Abstract)

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line injectable treatments. We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the placebo-controlled phase of the ADVANCE trial, a study of patients (...) with relapsing-remitting multiple sclerosis.We did this 2-year, double-blind, parallel group, phase 3 study, with a placebo-controlled design for the first 48 weeks, at 183 sites in 26 countries. Patients with relapsing-remitting multiple sclerosis (age 18-65 years, with Expanded Disability Status Scale score ≤5) were randomly assigned (1:1:1) via an interactive voice response or web system, and stratified by site, to placebo or subcutaneous peginterferon beta-1a 125 μg once every 2 weeks or every 4 weeks

2014 EvidenceUpdates Controlled trial quality: predicted high

173. Teriflunomide - Multiple Sclerosis, relapsing

Teriflunomide - Multiple Sclerosis, relapsing Common Drug Review CDEC Meeting — May 21, 2014 Notice of Final Recommendation — June 18, 2014 Page 1 of 6 © 2014 CADTH CDEC FINAL RECOMMENDATION TERIFLUNOMIDE (Aubagio — Genzyme Canada) Indication: Relapsing-Remitting Multiple Sclerosis Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that teriflunomide not be listed at the submitted price. Reasons for the Recommendation: 1. Two randomized controlled trials (RCTs) (TOWER (...) and TEMSO) demonstrated that the annualized relapse rate was lower with teriflunomide compared with placebo for patients with relapsing-remitting multiple sclerosis (RRMS) and one RCT (TENERE) demonstrated no statistically significant difference in the annualized relapse rate between teriflunomide and interferon beta-1a. 2. At the submitted price, teriflunomide ($vvvvvv per year) is more costly than glatiramer acetate ($16,241 per year) and interferon beta-1b (Extavia) ($18,133 per year). CDEC concluded

2014 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

174. Multiple sclerosis: monitor for the cardiac risks of fingolimod (Gilenya)

Multiple sclerosis: monitor for the cardiac risks of fingolimod (Gilenya) Prescrire IN ENGLISH - Spotlight ''Multiple sclerosis: monitor for the cardiac risks of fingolimod (Gilenya°)'', 1 January 2014 {1} {1} {1} | | > > > Multiple sclerosis: monitor for the cardiac risks of fingolimod (Gilenya°) Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight (...) Multiple sclerosis: monitor for the cardiac risks of fingolimod (Gilenya°) Starting a treatment with fingolimod, or resuming it after a break, exposes the patient to excessive slowing of the heart rate and requires close cardiac monitoring for several hours. Fingolimod is authorised for the treatment of multiple sclerosis in patients who do not respond to beta interferon therapy, or who have a severe, rapidly progressing disease. Compared with beta interferon treatment, fingolimod appears to reduce

2014 Prescrire

175. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial (Abstract)

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial Patients who develop relapsing-remitting multiple sclerosis (MS) present with a first clinical demyelinating event. In this double-blind, multicentre, randomised, phase 3 study we investigated the effect of oral cladribine on conversion to clinically definite MS in patients with a first clinical demyelinating event, when

2014 EvidenceUpdates Controlled trial quality: predicted high

176. Information provision for people with multiple sclerosis. (Abstract)

Information provision for people with multiple sclerosis. People with multiple sclerosis (MS) are confronted with a number of important uncertainties concerning many aspects of the disease. Among others, these include diagnosis, prognosis, disease course, disease-modifying therapies, symptomatic therapies and non-pharmacological interventions. It has been shown that people with MS demand adequate information to be able to actively participate in medical decision making and to self-manage (...) to promote informed choice and improve patient-relevant outcomes.We searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group Specialised Register which contains trials from CENTRAL (The Cochrane Library 2013, Issue 6), MEDLINE, EMBASE, CINAHL, LILACS, PEDro and clinical trials registries (12 June 2013) as well as other sources. In addition, we searched PsycINFO, trial registries, and reference lists of identified articles. We also contacted trialists.Randomised

2014 Cochrane

177. A systematic review of pharmacological pain management in multiple sclerosis

A systematic review of pharmacological pain management in multiple sclerosis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2014 DARE.

178. Mycophenolate mofetil for relapsing-remitting multiple sclerosis. (Abstract)

Mycophenolate mofetil for relapsing-remitting multiple sclerosis. Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system and a leading cause of disability in young and middle-aged adults. Mycophenolate mofetil (MMF) is an immunosuppressive agent that has been used for the prevention of allograft rejection after renal, cardiac, or liver transplant and in patients with autoimmune diseases such as active relapsing-remitting (RRMS) and progressive MS.To assess (...) the efficacy and safety of MMF for preventing disease activity in patients with RRMS.We searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group Specialised Register (January 14, 2013). We searched three Chinese databases (January 2013) and checked reference lists of identified trials. We contacted authors and pharmaceutical companies to ask for additional information. We applied no language restrictions.We included randomized controlled trials with a follow-up

2014 Cochrane

179. Treatment of patients with multiple sclerosis: a review of guidelines

Treatment of patients with multiple sclerosis: a review of guidelines Treatment of patients with multiple sclerosis: a review of guidelines Treatment of patients with multiple sclerosis: a review of guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Treatment of patients with multiple sclerosis: a review of guidelines (...) . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions Limited evidence-based guidelines are available for the treatment of multiple sclerosis, and the stopping or switching of treatment. The available evidence has suggested plasmapheresis as an adjunctive or alternative treatment for MS, corticosteroids for the treatment of relapse, and natalizumab in cases of failure on other drugs or intolerance. Final

2014 Health Technology Assessment (HTA) Database.

180. An RCT to treat learning impairment in multiple sclerosis: The MEMREHAB trial Full Text available with Trip Pro

An RCT to treat learning impairment in multiple sclerosis: The MEMREHAB trial To examine the efficacy of the modified Story Memory Technique (mSMT), a 10-session behavioral intervention teaching context and imagery to facilitate learning, to improve learning and memory abilities in persons with multiple sclerosis (MS).This double-blind, placebo-controlled, randomized clinical trial included 86 participants with clinically definite MS, 41 in the treatment group and 45 in the placebo control

2014 EvidenceUpdates Controlled trial quality: predicted high